n-phthaloylglutamic acid has been researched along with 2-(2,6-dioxopiperidin-3-yl)phthalimidine in 1 studies
| Studies (n-phthaloylglutamic acid) | Trials (n-phthaloylglutamic acid) | Recent Studies (post-2010) (n-phthaloylglutamic acid) | Studies (2-(2,6-dioxopiperidin-3-yl)phthalimidine) | Trials (2-(2,6-dioxopiperidin-3-yl)phthalimidine) | Recent Studies (post-2010) (2-(2,6-dioxopiperidin-3-yl)phthalimidine) |
|---|---|---|---|---|---|
| 8 | 0 | 0 | 21 | 0 | 2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Browne, F; D'Amato, RJ; Kenyon, BM | 1 |
1 other study(ies) available for n-phthaloylglutamic acid and 2-(2,6-dioxopiperidin-3-yl)phthalimidine
| Article | Year |
|---|---|
Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization.
Topics: Administration, Oral; Animals; Cornea; Corneal Neovascularization; Endothelial Growth Factors; Female; Fibroblast Growth Factor 2; Glutamates; Injections, Intraperitoneal; Lymphokines; Mice; Mice, Inbred C57BL; Structure-Activity Relationship; Teratogens; Thalidomide; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 1997 |